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122Background: Left ventricular hypertrophy is associated with adverse cardiovascular outcomes. It is unclear
whether hypertrophy caused by severe chronic mitral regurgitation regresses after mitral valve repair and, if
so, which factors promote reverse remodeling and influence its prognostic significance.
Methods: Between March 1995 and December 2005, 2589 patients had mitral valve repair. Five hundred thirty
patients (346 of whom were male) underwent isolated repair for leaflet prolapse and had echocardiographic data
available from which the left ventricular mass index could be calculated. Concomitant preoperative tricuspid
valve regurgitation was more than mild in 95 (18%) patients. Thosewith preoperative atrial fibrillation and other
cardiac pathologies necessitating intracardiac repair were not included.
Results: Significant regression of left ventricular mass index occurred during the first 3 years (28 g/m2,
P<.001) and was maintained during follow-up for more than 3 years (26 g/m2, P<.001). Higher preoperative
left ventricular ejection fraction and greater preoperative left ventricular mass index independently predicted
improved left ventricular mass index regression at 3 years. During follow-up of greater than 3 years, greater pre-
operative left ventricular mass index persisted in predicting improved mass regression (P<0.001), and greater
than mild preoperative tricuspid valve regurgitation was associated with less mass regression (P<.001). Late
recovery of normal left ventricular ejection fraction was impaired in those with the greatest residual left ventric-
ular mass; however, there was no difference in late symptoms or survival.
Conclusions: Performing mitral valve repair before a decrease in left ventricular ejection fraction and the de-
velopment of significant secondary tricuspid valve regurgitation is associated with a greater likelihood of sig-
nificant regression of left ventricular mass, possibly predicting improved recovery of normal left ventricular
function after surgical intervention. These data provide additional support for early degenerative mitral valve
repair. (J Thorac Cardiovasc Surg 2011;141:122-9)Although recovery of normal left ventricular (LV) geometry
and function via favorable LV remodeling is know to occur
after mitral valve repair,1,2 it is unclear whether significant
LV mass regression proceeds concurrently and, if so, which
factors predict improved long-term normalization of left
ventricular hypertrophy (LVH). It is known that incomplete
regression of LV mass is associated with poor long-term
outcomes after aortic valve replacement for aortic steno-
sis3-6 and during medical therapy for hypertension.7-9
The goals of this study were to document changes in left
ventricular mass index (LVMI) after isolated mitral valve
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The Journal of Thoracic and Cardiovascular Surgfavorable LV remodeling. We also sought to correlate the
regression of LVMI with late outcomes, including recovery
of normal left ventricular ejection fraction (LVEF), func-
tional status, adverse cardiac events, and survival, to deter-
mine its prognostic significance.MATERIALS AND METHODS
The Mayo Foundation Institutional Review Board approved this study,
and all patients or their families provided written informed consent.
Patients
From March 1995 to December January 2005, 2589 patients had mitral
valve repair at Mayo Clinic in Rochester, Minnesota. Of these, we identi-
fied 530 patients (346 men; median age, 63 years; range, 22–89 years) who
underwent mitral valve repair for severe mitral regurgitation (MR) caused
by isolated leaflet prolapse and who had echocardiographic data available
from which LVMI could be calculated. We included those who had coex-
istent, clinically silent, functional tricuspid valve regurgitation (TR) that
was less than severe, not associated with right heart failure symptoms or
significant right ventricular dysfunction, and not related to a structural tri-
cuspid valve abnormality. Patients with MR caused by congenital abnor-
malities, rheumatic or ischemic heart disease, or endocarditis resulting in
leaflet destruction were excluded from this study. We also excluded those
with a preoperative history of atrial fibrillation or concomitant cardiac
pathology necessitating combined operations at the time of mitral valve
repair.ery c January 2011
TABLE 2. Mean preoperative NYHA functional class
Patient group NYHA class P value
Entire cohort 1.9  0.8
Male patients 1.8  0.8
Female patients 2.1  0.8 .4
Hypertension 2  0.8
No hypertension 1.8  0.8 .32
TABLE 1. Mean preoperative LVMI values
Patient group
No. of
patients LVMI (g/m2)
Multiple of
normal P value
Entire cohort 530 128  30 1.9
Male patients 131  28 1.8
Female patients 120  31 2.0 .56
Hypertension 193 128  30 1.9
No hypertension 337 127  29 1.9 .89
LVMI terciles
115 g/m2 175 96  14 1.4
115–140 g/m2 178 127  7 1.9
140 g/m2 177 160  19 2.4 .03
Preoperative TR
None 32 115  18 1.7
Trivial–mild 403 128  28 1.9
Moderate 95 129  42 1.9 .17
LVMI, Left ventricular mass index; TR, tricuspid valve regurgitation.
Abbreviations and Acronyms
HR ¼ hazard ratio
LV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
LVH ¼ left ventricular hypertrophy
LVMI ¼ left ventricular mass index
MR ¼ mitral regurgitation
TR ¼ tricuspid valve regurgitation
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prolapse, which is the most frequent mitral valve pathology encountered in
the Western world. This specific study period was chosen because tech-
niques used during this era reflect our contemporary approach to mitral
valve repair while ensuring capture of a representative follow-up period.
Clinical Characteristics
Preoperative TR was graded as none in 32 (6%) patients, trivial–mild in
403 (76%) patients, and moderate in 95 (18%) patients. The patient cohort
did not have a high prevalence of significant comorbidities. Important pre-
operative clinical characteristics included hypertension in 193 (36%) pa-
tients, chronic obstructive pulmonary disease in 21 (4%) patients, and
diabetes in 16 (3%) patients. Mitral valve pathology included isolated pos-
terior leaflet prolapse in 286 (54%) patients, bileaflet prolapse in 212
(40%) patients, and isolated anterior leaflet prolapse in 32 (6%) patients.
Echocardiographic Analysis
Preoperative, postoperative, and follow-up evaluation of MR and TR
was obtained by means of 2-dimensional and Doppler echocardiographic
analysis. Severity of regurgitation was classified as 0 (none), 1 (trivial), 2
(mild), 3 (moderate), 3.5 (moderate–severe), and 4 (severe). LV mass
was calculated with the corrected American Society of Echocardiography
formula10 using 2-dimensional, M-mode, or 2-dimensional linear LV sur-
face echocardiographic measurements. This calculation of LVMI is as fol-
lows:
LV mass ðgÞ ¼ 0:80½1:04fPWTDþLVIDþLISWTÞ3  LVID3 þ0:6g .
The obtained result was indexed for body surface area in grams per
square meter, with LVID defined as LV internal dimension in diastole,
IVSD defined as interventricular septum dimension in diastole, and
PWTD defined as posterior wall thickness in diastole. These methods
have been validated in both animal models and human autopsy studies11
and have been used in large population-based studies analyzing changes
in LV mass in hypertensive patients.12,13 We defined the normal values for
LVMI in this study as 71 g/m2 for male patients and 60 g/m2 for female
patients, and LVH was considered present when LVMI was 134 g/m2 or
greater for male patients and 110 g/m2 or greater for female patients.14,15
Taking into account the distribution of sex in this cohort, the calculated
normal value used for LVMI overall in this study taken as a group was 67
g/m2, and the criteria for LVH was 125 g/m2 or greater. This was done by
adding the product of the percentage of male patients and the normal
LVMI value for male patients to the product of the percentage of female
patients and the normal LVMI value for female patients.LVMI terciles
115 g/m2 2  0.9
115–140 g/m2 1.8  0.7
140 g/m2 1.9  0.9 .56
NYHA, New York Heart Association; LVMI, left ventricular mass index.Preoperative Data
Mean preoperative LVMI values are shown in Table 1, and mean preop-
erative New York Heart Association (NYHA) functional classes are shown
in Table 2.The Journal of Thoracic and CaStatistical Analysis
Demographic and other patient-related data were obtained from Mayo
Clinic medical records and our prospective clinical database. Follow-up in-
formation was obtained from subsequent clinic visits, written correspon-
dence from local physicians, and mailed questionnaires to patients or
families. Continuous data were expressed as either means  standard de-
viations or medians with ranges. Risk factors were assessed by using
log-rank analysis. Variables significant in the univariate analysis were
used during stepwise selection to create the final multivariable model. Sur-
vival was determined by using Kaplan–Meier analysis. Early operative
mortality was defined as death occurring within 30 days of the operation
or at any time during the index hospitalization.
RESULTS
All patients underwent isolated mitral valve repair for se-
vere MR caused by leaflet prolapse. The most commonly
used techniques for mitral valve repair have been described
elsewhere.16,17 The closing interval for this cohort was 3
months, and median echocardiographic follow-up was 3.5
years (maximum, 13.1 years). Echocardiographic data
were grouped into the following categories: preoperative,
3 years or less, and greater than 3 years.
LV Mass Regression and LVEF
Significant regression of LVMI (all compared with base-
line values) occurred during the first 3 years to a mean ofrdiovascular Surgery c Volume 141, Number 1 123
FIGURE 2. Change in left ventricular mass index (LVMI) according to the
degree of preoperative LVMI during follow-up intervals is shown. Less re-
gression of LVMI was noted in the highest tercile cohort at 3 years or less
and greater than 3 years compared with the lower 2 terciles (P< .001).
Multiples of normal values are shown on the right.
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26 g/m2 (1.53 normal value) during follow-up of longer
than 3 years (P<.001, Figure 1). There was similar regres-
sion of LVMI for male patients (31 g/m2 at 3 years and
30 g/m2 at >3 years, P < .001) and female patients
(23 g/m2 at 3 years and 21 g/m2 at >3 years,
P<.001), with no significant difference between the groups
(P¼ .66). Patients with preoperative hypertension had sim-
ilar LVMI regression (27 g/m2 at3 years and31 g/m2 at
>3 years, P< .001) compared with that seen in patients
without hypertension (28 g/m2 at 3 years and25 g/m2
at>3 years, P<.001); there was no significant difference
between the groups (P ¼ .34). We divided patients into ter-
ciles based on the degree of preoperative LVMI. At the 3
years or less and greater than 3 years time points, respec-
tively, patients with preoperative LVMI in the 115 g/m2 or
less tercile had LVMI regression of10 g/m2 and7 g/m2
(P ¼ .88), those with preoperative LVMI of 115 to 140 g/
m2 had regression of29 g/m2 and28 g/m2 (P< .026),
and those in the 140 g/m2 or greater tercile had regression
of 47 g/m2 and 43 g/m2 (P < .001), respectively
(Figure 2). By tercile, LVMI regressed to 1.33, 1.53, and
1.73 normal values, respectively. The incidence of
recurrent moderate or greater MR was not significantly dif-
ferent among preoperative groups at both the 3 years or less
(115 g/m2, 3%; 115–140 g/m2, 4%; and >140 g/m2,
10%; P ¼ .34) and greater than 3 years (115 g/m2,
10%; 115–140 g/m2, 10%; and >140 g/m2, 12%;
P ¼ .72) time points.
At greater than 3 years’ follow-up, patients with no pre-
operative functional TR had26 g/m2 regression of LVMI
to 89 g/m2 (1.33 normal value), whereas those with trivial
to mild TR had LVMI regression of28 to 100 g/m2 (1.53
normal value). Those with moderate TR had LVMI regres-
sion of only17 to 112 g/m2 (1.73 normal value, P<.001,FIGURE 1. Change in left ventricular (LV) mass index during follow-up
intervals is shown. There is a significant decrease in LV mass index at 3
years or less and greater than 3 years compared with preoperative values
(P<.001). Multiples of normal values are shown on the right.
124 The Journal of Thoracic and Cardiovascular SurgFigure 3). The following variables were independently as-
sociated with greater LVMI regression during the first 3
years of follow-up: greater preoperative LVEF (hazard ratio
[HR], 0.89 [95% confidence interval, 1.6, 0.2];
P ¼ .013) and greater preoperative LVMI (HR, 0.59
[95% confidence interval, 0.75, 0.4]; P < .001). At
follow-up past 3 years, greater preoperative LVMI remained
independently associated with greater LVMI regression
(HR, 0.55 [95% confidence interval, 0.72, 0.4];
P<.001), whereas moderate preoperative TR was predic-
tive of significantly less LVMI regression (HR, 16.7 [95%
confidence interval, 2.9, 30.5], P ¼ .017).
Preoperative LVEF was 65%, 67%, and 65% in the 115
g/m2 or less, 115 to 140 g/m2, and greater than 140 g/m2
groups, respectively. Within 3 years of follow-up, LVEF de-
creased to 61%, 59%, and 57% in the 115 g/m2 or less, 115FIGURE 3. Change in left ventricular (LV) mass index according to de-
gree of preoperative tricuspid valve regurgitation (TR) during late
follow-up at of greater than 3 years is shown. There is a significant differ-
ence in LVmass index regression between patients with no and trivial–mild
preoperative TR compared with that seen in patients with moderate preop-
erative TR (P<.001).
ery c January 2011
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respectively (P¼ .06). At follow-up of greater than 3 years,
LVEF stabilized at 62% and 60% in the 115 g/m2 or less
and 115 to 140 g/m2 groups, respectively, but continued
to decrease in the greater than 140 g/m2 group to 53%
(P ¼ .007; Figure 4, A). Similarly, LV end-systolic dimen-
sion was greatest in the highest LVMI tercile preoperatively.
Whereas patients in the lowest 2 terciles had a decrease
in LV end-systolic dimension with time, those with the
greatest LVMI were significantly impaired in their ability
to remodel toward more normal dimensions during
follow-up (Figure 4, B).
NYHA Functional Class
For the entire cohort, NYHA functional class signifi-
cantly improved from 1.9  0.8 preoperatively to 1.4 
0.7 at last follow-up (P<.001); 70% of patients were in
NYHA functional class I at follow-up (compared with
38% preoperatively, P<.001). Male patients had similar
postoperative recovery of NYHA functional class I statusFIGURE 4. A, Change in left ventricular ejection fraction (LVEF) accord-
ing to the degree of preoperative left ventricular mass index (LVMI) during
follow-up intervals is shown. There is a significant difference in LVEF at
greater than 3 years in the greater than 140 g/m2 group compared with
the 115 g/m2 or less and 115 to 140 g/m2 groups (P<.001). B, Change
in left ventricular end-systolic dimension (LVESD) according to degree
of preoperative LVMI during follow-up intervals is shown. There is a signif-
icant difference in LVESD at all time points (P<.01).
The Journal of Thoracic and Cawhen compared with female patients (P ¼ .62). Although
patients in each tercile based on preoperative LVMI had sig-
nificant improvement in NYHA functional class during
follow-up, there was no significant difference among the 3
groups (P ¼ .64).Late Nonfatal Morbidity
Responses to follow-up questionnaires inquiring about
late adverse events were obtained in 382 (72%) patients.
Thirty-three (8.7%) patients were in NYHA functional
class III or IV, and 2 (0.005%) patients had a late myocar-
dial infarction. Seven (1.9%) patients underwent a reopera-
tion on the mitral valve, and all but 1 patient had mitral
valve re-repair. Overall actuarial freedom from late stroke
was 96% at 10 years, which was similar between patients
with (96%) and without (95%) preoperative hypertension
(P ¼ .91). Late freedom from stroke at 10 years was also
not significantly different when stratified by preoperative
LVMI tercile (115 g/m2, 97%; 115–140 g/m2, 98%;
and 140 g/m2, 93%; P ¼ .77).Late Survival
Median late follow-up for determination of vital status
was 4.9 years (maximum, 13.1 years). Overall late actuarial
survival for the entire cohort was 94.4% at 5 years and
81.1% at 10 years. Late survival was similar among patients
within each tercile of preoperative LVMI: 94% at 5 years
and 81% at 10 years for the 115 g/m2 or less group, 94%
at 5 years and 84% at 10 years for the 115 to 140 g/m2
group, and 95% at 5 years and 79% at 10 years for the
140 g/m2 or greater group (P¼ .99; Figure 5, A). Decreased
preoperative LVEF (HR, 1.04 [1.02–1.11]; P ¼ .001),
advanced age (HR, 1.11 [1.08–1.13]; P < .001), and
preoperative renal insufficiency (HR, 3.43[1.2–9.5];FIGURE 5. Overall actuarial survival according to the degree of preoper-
ative left ventricular mass index is shown. There is no significant difference
between groups during late follow-up.
rdiovascular Surgery c Volume 141, Number 1 125
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survival.
DISCUSSION
Performing mitral valve repair for leaflet prolapse before
a decrease in preoperative LVEF and the development of
moderate functional TR predicts a greater likelihood of
more complete regression of LVMI after surgical interven-
tion. Although greater preoperative LVMI did result in
greater percentage regression of LVMI during follow-up,
these patients retained greater residual LVMI (1.73 normal
value) and had less recovery of normal LV function and
dimensions when compared with those with less initial pre-
operative LVMI. Preoperative LVMI likely reflects the de-
gree of adverse LV remodeling in patients with chronic
MR and might help guide the timing of early mitral valve
repair.
The effect of excess LV mass has perhaps been best stud-
ied in hypertensive patients and those with aortic valve ste-
nosis. Regression of echocardiographic LVH during
treatment for hypertension has been shown to reduce car-
diac risk,18 whereas inappropriate or incomplete LV mass
regression is associated with adverse outcomes and ventric-
ular contractile dysfunction.19 Similarly, after aortic valve
replacement for severe aortic stenosis, the most important
predictor of diminished LV mass regression was the extent
of preoperative LVMI, whereas survival and heart failure
were not influenced by the extent of regression. Some
have suggested that earlier surgical intervention for severe
aortic valve stenosis might be the most important factor in
facilitating postoperative normalization of LVMI; however,
the potential effect on long-term survival must be studied
further in the absence of definitive scientific evidence.20
Prior data have established that early mitral valve repair
before the onset of symptoms or LV dysfunction (LVEF
<60% or LVend-systolic dimension40 mm) is important
for normalization of late survival, optimization of reverse
LV remodeling, and recovery of LVEF.1,2,21-23 Recent
reports point to even more advanced indications for
optimization of LV functional recovery. Enriquez-Sarano
and Sundt24 have recently published a formalized rationale
for early mitral repair. First, because only a small fraction of
patients remain alive and free from operation in the long-
term after the diagnosis of organic mitral valve regurgita-
tion, surgical intervention is largely unavoidable. Second,
by the time class I indications for surgical intervention
(LVEF 60% or LV end-systolic dimension 40 mm)
have been met, patients are already at significantly in-
creased risk for higher overall mortality compared with
those without symptoms.25 Third, early mitral valve repair
has been demonstrated to restore life expectancy to nor-
mal.26 Fourth, patients with organic MR under medical
management possess not only increased mortality27 but
have twice the risk of sudden death compared with the126 The Journal of Thoracic and Cardiovascular Surggeneral population.28 Finally, there is no alternativemedical
treatment that is equivalent to early mitral valve repair.24
Currently, the degree of LV mass is not included in the
guidelines for the timing of mitral valve repair for severe
MR.21,22 In this study, the following preoperative factors
predicted less complete regression of LVMI after mitral
valve repair: diminished preoperative LVEF, preoperative
moderate functional TR, and greater degrees of
preoperative LVMI. Not surprisingly, we found that
regression of LVMI after mitral valve repair was
accompanied by significant improvement in NYHA class
during follow-up. Perhaps counterintuitive was the finding
that functional improvement was also seen when patients
were grouped according to degree of preoperative LV
mass. The lack of association between incomplete LV
mass regression and worse functional status has also been
observed after aortic valve replacement for aortic steno-
sis.20 To our knowledge, there are very few data demonstrat-
ing that poor LV mass regression is associated with
impaired functional status after surgical correction of heart
valve disease. Even though patients with the highest degrees
of preoperative LVMI (>23 normal value) had incomplete
reverse remodeling compared with those with lower LV
mass, regression below the accepted cutoff point for the
echocardiographic criteria of LVH still occurred. Similarly,
we demonstrate that overall survival was not affected by in-
complete LVmass regression, which has also been observed
after aortic valve replacement.20 The majority of informa-
tion about LV mass and its relation to long-term survival
comes from the hypertension literature,29,30 and although
current evidence demonstrates poor long-term survival
with LVH in these patients, there is little evidence that LV
mass regression itself affects survival. In contrast, incom-
plete regression of LV mass has been associated with an in-
creased risk of stroke, and some have suggested that reverse
remodeling might decrease this risk.31 The major effect of
incomplete LV mass regression demonstrated in the current
series was failure of LV function to recover during late
follow-up; patients with the greatest degree of preoperative
LVMI (>23 normal value) had a significant and progres-
sive decline in LVEF, whereas those with less preoperative
LVMI benefitted from stabilization and recovery of LVEF
over time.
Our understanding of the prognostic significance of pre-
operative LVH in patients with chronic MR is still nascent.
Recently, Song and colleagues32 examined ventricular re-
verse remodeling early after mitral valve repair for severe
MR in patients with concomitant atrial fibrillation. They
sought to determine whether preoperative clinical, echocar-
diographic, and N-terminal B-type natriuretic peptide could
predict postoperative LV reverse remodeling after mitral
valve repair and a modified maze procedure. Important dif-
ferences between their study and our own include the follow-
ing: (1) all patients in the former study underwent amodifiedery c January 2011
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(2) all patients had atrial fibrillation; and (3) there was
important heterogeneity in the cause of mitral valve disease,
including rheumatic pathology. Furthermore, in the study by
Song and colleagues,32 patients with failure of LV mass re-
gressionwere older andmore likely to have preoperative hy-
pertension, and preoperative N-terminal B-type natriuretic
peptide negatively influenced the capacity for LV mass re-
gression. Those who did undergo reverse remodeling did
so early after surgical intervention, which correlated with
progressive recovery of LVEF and normalization of LV
end-diastolic/end-systolic dimensions during follow-up in
a manner consistent with our prior investigations.1 As
Song and colleagues32 suggest, the capacity for favorable re-
verse ventricular remodeling might diminish with time as
a consequence of prolonged exposure to chronic uncorrected
MR, leading to irreversible pathologic fibrotic change and
diminishedmass regression, even after effectivemitral valve
repair. Our data support this hypothesis; those in the highest
tercile of preoperative LV mass (>23 normal value) had
both less effective regression of LV mass and diminished
ejection fraction recovery with time.
Limitations
This study cohort is intentionally homogeneous to better
understand the clinicopathologic relationship between LV
mass and clinical/echocardiographic outcomes in a group
of patients with isolated leaflet prolapse undergoing early
isolated mitral valve repair. It is clearly understood that
the results might not be generalizable to all patients under-
going mitral valve surgery. The patients in this study were
also selected on the basis of having echocardiographic
data available for LVMI calculations; others who met
inclusion criteria but lacked this information were not in-
cluded in this report. Follow-up questionnaires were obtain-
able in approximately 75% of patients, and although this
represented the most complete effort possible, we recognize
the fact that late data from one quarter of the patient cohort
were not analyzed. Although the absence of this information
might affect the detected prevalence of late events, we have
no reason to believe that those who were lost to follow-up
were systematically excluded for some distinguishing fea-
ture. It remains possible, however, that those who were
available for clinical or echocardiographic follow-up had
a higher prevalence of certain clinical features. Despite
demonstrating that greater LVmass adversely affects the re-
covery of normal LV function, one possible reason we failed
to identify an effect on clinical outcome might have been
our programmatic adherence to a principle of early mitral
valve repair surgery for severe MR before symptom onset
or LV dysfunction. We acknowledge that data regarding
the effectiveness of antihypertension or afterload reduction
therapy after mitral valve repair in this study are sparse. We
are currently planning studies to investigate the potentialThe Journal of Thoracic and Carole that these therapies might play in influencing LV
mass regression after mitral valve repair surgeryCONCLUSIONS
Performing early mitral valve repair before the develop-
ment of severe LVH greater than twice normal, decline in
preoperative LVEF, or the development of significant func-
tional TR is associated with an improved likelihood of sig-
nificant regression of LV mass after surgical correction.
Patients with the greatest degree of residual postoperative
LV mass are limited in their ability to recover normal LV
systolic function with time after mitral repair, although
late functional capacity, adverse cardiac events, and sur-
vival do not appear to be affected in this preliminary analy-
sis. These data provide additional support for early valve
repair for leaflet prolapse to optimize favorable LV remod-
eling and recovery of normal LV systolic function.References
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Dr David H. Adams (New York, NY). By way of disclosure, I
am an inventor with a royalty agreement with Edwards.
John, I would like to congratulate you on a job well done with
your presentation and manuscript. We all admire the enormous
contributions from the Mayo Clinic to our understanding of the
timing for intervention in mitral valve disease, most recently sum-
marized in an excellent review published earlier this year in Circu-
lation by Maurice Sarano and our Secretary, Thor Sundt.
Essentially, all the class I triggers for intervention in the guide-
lines, including LV end-systolic dimension, ejection fraction, and
the development of symptoms, result from clinical research from
the Mayo Clinic.
In this article you attempt to add significant LVH to the list of
potential indications for valve repair in patients with prolapse. Al-
though I agree with the benefit of operating on patients with severe
regurgitation early in the course of their disease to protect the ven-128 The Journal of Thoracic and Cardiovascular Surgtricle, I am not convinced yet that your study has provided suffi-
cient data to elevate LVH or the likelihood of ventricular
remodeling to our list of triggers. I have a few questions.
You mentioned early surgical intervention in the title of your ar-
ticle, which is never really defined. I know your institution has
been a leading proponent of early surgical intervention in asymp-
tomatic patients with preserved LV function, and therefore I would
like to understand your data in this context. Your landmark article
first authored by Seano on this topic was published in 2005, yet
surely many patients in this study were operated on in an early set-
ting because that particular article took a few years to actually
come out in print. The LVEF was 65% or greater in all 3 terciles,
and you did you not see a difference in functional class between
cohorts. Therefore there seems no clear indication that higher
LVMI in selected patients reflected delayed surgical intervention.
Can you tell us what exactly you define as early surgical interven-
tion and also the proportion of patients in each tercile defined by
LVMI who had early surgical intervention as you define it?
Dr Stulak. Thank you, Dr Adams. We appreciate you being our
discussant. At Mayo Clinic, we operate on patients who are well
within class I and class IIA indications; however, prior studies
from our institution have demonstrated superior outcomes when
operations are undertaken when the LVEF is between 60% and
65% and when the LV end-systolic dimension is between 36 and
40 mm. That is what we define as the criteria for early mitral valve
repair.
Dr Adams. Can you tell us why LVMI was not quantifiable in
approximately 15% of your cohort? You excluded about 15% of
patients, saying you could not calculate LVMI. Can you tell us
why that was and what your protocol was for defining it?
Dr Stulak. This study period was from 1995 to 2005. Standard-
ization of the reporting of echocardiographic data did not become
common practice until the late 1990s. Therefore the most com-
monly missed measurement was posterior wall thickness. For
the calculation of LVMI, we used the equation set forth by the
American Society of Echocardiography. I would surmise that
those 15% of patients probably were lost during that lack of stan-
dardization time period.
Dr Adams. John, in another article from your institution this
year, a preoperative LV end-systolic dimension of greater than
40 mm was identified as a predictor of late mortality after mitral
valve repair. Why do you think a high LVMI was not associated
with late mortality? Do you think hypertension in more than a third
of your patients is the confounder that really explains this?
Dr Stulak. We were surprised at the finding that there is no dif-
ference in late survival, and I believe that there are several reasons
to explain this finding. First, hypertension could have been a con-
founder; however, this was not found to be independently associ-
ated with a multivariable model. Furthermore, patients with and
without hypertension had a similar degree of LV mass regression.
Second, this is a retrospective study using historical echocardio-
graphic data and obvious limitations exist. Third, it is a highly se-
lected patient population with a single cause of MR. This lack of
difference in survival actually is what has been observed in studies
examining patients with aortic stenosis who have had incomplete
mass regression. Therefore I think that prospective collection of
data in a larger patient population is warranted beforewe can really
draw firm conclusions.ery c January 2011
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DDrAdams. And, of course, we need to know better how that hy-
pertension gets managed.
Dr Stulak. Absolutely.
Dr Adams. My last question is this: Given the detrimental ef-
fect of LVH on LV function, do you think we should incorporate
LVMI in our future decision-making algorithms and guidelines?
Specifically, in a patient with normal ventricular function, an ejec-
tion fraction of 70%, normal dimension, LV systolic dimension of
34 mm, and severe MR, would you regard a low or normal LVMI
as an indication that watchful waiting rather than surgical interven-
tion would be an appropriate strategy? In other words, are you go-
ing to counsel patients? I understand that if they have a high LVMI,
you are going to say that they should have an operation, but would
a completely normal LVMI maybe sway you toward watchful
waiting?
Dr Stulak. Another great question. I do not think that LV mass
rises to the same bar as ejection fraction and LV end-systolic di-
mension. Prior studies from our institution have documented ex-
cellent outcomes if the ejection fraction is normal and the LV
end-systolic dimension is normal. I do not believe this study is de-
signed to answer that question, but I do not think that a low LVMI
would affect our decision to undertake surgical intervention in
patients presenting early.
Dr Adams. John, congratulations.
DrA.W.Atkinson (Raleigh, NC). I just want to touch on a point
that Dr Adams made, and I think it was in your discussion about
the confounding of hypertension. In particular, do you have any
data on the postoperative management with afterload reduction
until a return of normal LVMI?
Dr Stulak. That is an outstanding question, and this is certainly
one of the limitations of this study. Although some patients are fol-
lowed very aggressively at Mayo Clinic by the cardiologists, we do
lose certain patients from distances to the community and their
personal primary care physicians. Those followed at Mayo ClinicThe Journal of Thoracic and Caare treated with an aggressive regimen of b-blockade and angio-
tensin-converting enzyme inhibition. I think to overcome this lim-
itation, prospectively collected data and more accurate follow-up
of hypertension control are crucial.
Dr Rakesh M. Suri (Rochester, Minn). John has done a fan-
tastic job on this study. I just wanted to comment on Dr Adams’
question. Of course, this is a very unique cohort of patients who
all underwent early mitral valve surgery well within class I or
class IIa guidelines, and as such, the findings are not surprising.
They all have good late survival and a low incidence of late
complications or stroke. The study was designed to characterize
the change in LV mass following mitral valve repair and to un-
derstand factors influencing regression of ventricular hypertro-
phy. The separate question as to whether we can safely wait
to allow LVH to develop cannot be addressed within the current
study. Previous series have clearly demonstrated, however, that
‘‘watchful waiting’’ of patients severe MR once guideline-based
surgical indications have been met, is associated with dire clin-
ical consequences.
DrHarold L. Lazar (Boston, Mass). I just want to follow up on
the questions that Dr Adams raised about the pathophysiology for
the mass regression. Did you look at the patients you actually ex-
cluded from the study, those with atrial fibrillation and coronary
artery disease, to see whether there was a similar change in mass
regression? In other words, does the presence of atrial fibrillation
or coronary artery disease inhibit mass regression in patients who
have valve repair for posterior leaflets?
Dr Stulak. That is an outstanding point, and we are currently
actually looking at each different subset of those 2600 mitral valve
repairs from all causes. Again, we wanted to start our investigation
with a homogenous population, taking every possible confounding
effect of cause out of the equation. Then, on interpreting our re-
sults, we were very enticed. Therefore we are going to extend
this to larger groups of patients. You make a great point.rdiovascular Surgery c Volume 141, Number 1 129
